Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Randomized, Placebo-Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin (FCT)

NCT02410902 is registered in ClinicalTrials.gov with Curemark as lead sponsor.

NCT NCT02410902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02410902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Randomized, Placebo-Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin (FCT)
Lead sponsor
Curemark
Phase
Phase 3
Overall status
Completed
Start date
May 13, 2015
Completion date
December 22, 2017
Enrollment
190 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

autism